Comparing different forms of nicotine in vaping
Official title: Comparative Pharmacokinetics and Pharmacodynamics of Synthetic Nicotine
Run by University of California, San Francisco · NCT05962229 · Data updated 2026-11-12
This study is testing how different types of nicotine in vaping affect experienced users' cravings, withdrawal symptoms, and enjoyment while also looking at how their bodies process these forms of nicotine.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 21 Years to 65 Years |
| Sex | All |
| Enrollment | 18 (estimated) |
| Sponsor | University of California, San Francisco Academic / other |
| Locations | 1 site (San Francisco, California) |
| Status | Recruiting |
| Started | December 6, 2024 |
| Main results expected | May 2027 |
| Study ends | May 2027 |
| Registry record updated | May 14, 2026 |
| Trial ID | NCT05962229 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are healthy adults who are regular users of e-cigarettes for at least 15 days in the past month.
✕Probably not a fit
Patients who are pregnant, breastfeeding, or using certain medications that affect nicotine metabolism will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study involves experienced electronic cigarette users who will vape three different forms of nicotine: natural, synthetic, and a 50:50 mixture of both. It aims to compare how these forms of nicotine are metabolized in the body, their cardiovascular effects, and how they influence users' cravings, withdrawal symptoms, and enjoyment. Participants will undergo a crossover design, allowing them to experience each form of nicotine in a controlled setting. The findings could provide insights into the pharmacokinetics and pharmacodynamics of nicotine in vaping.
Why it matters
Potential benefit: If successful, this study could help inform better nicotine delivery methods and improve strategies for managing nicotine dependence.
How similar studies have gone: Other studies have explored nicotine pharmacokinetics, but this specific comparison of synthetic versus natural nicotine in vaping is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria:
* Healthy on the basis of medical history and limited physical examination.
* Current regular user of E-Cigarettes (≥ 15 days in the past 30 days)
Exclusion Criteria:
* • Medications
* Use of medications that are inducers of nicotine metabolizing enzyme CYP2A6 (Example: rifampicin, carbamazepine, phenobarbital, and other anticonvulsant drugs).
* Use of sympatholytic medications for cardiovascular conditions including hypertension (Example: beta and alpha-blockers).
* Concurrent use of nicotine-containing medications (Example: nicotine patch, lozenge, gum).
* Any stimulant medications (example: Adderall) generally given for ADHD treatment.
• Pregnancy
* Pregnancy (self-reported and urine pregnancy test)
* Breastfeeding (determined by self-report)
* Women of childbearing potential must be using an acceptable method of contraception
* Inability to read and write in English
* A known propylene glycol/vegetable glycerin allergy
* Uncomfortable with getting blood drawn
Where it's running
-
Zuckerberg San Francisco General Hospital (ZSFG)
San Francisco, California, United States Recruiting
Study contacts
- Principal investigator: Neal Benowitz, MD — University of California, San Francisco
- Study coordinator: Lisa Lawrence
- Email: lisa.lawrence@ucsf.edu
- Phone: 628-206-4204
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
How people puff IQOS Iluma i vs IQOS 2.4 and how flavors feel
This study tests how exclusive IQOS users puff the newer Iluma i versus the older 2.4, and whether preferred flavor affects puffing and sensory experience.
-
Do a single nicotine pouch affect cigarette craving and brain response to smoking cues
This study tests whether a single 6 mg oral nicotine pouch can reduce craving and alter prefrontal brain responses to smoking cues in adults who smoke cigarettes.
-
TUBSIS 2.0 — an online program to help adults reduce or quit smoking and vaping
This program tests whether a free, anonymous, 4-week web-based course using mindfulness, self-compassion, and behavior-change techniques helps German-, English-, and Turkish-speaking adults who smoke or vape reduce or quit tobacco.
-
Social media support groups to help teens and young adults quit vaping
This pilot tries a social-media group program called the Quit the Hit Toolkit to help adolescents and young adults who vape stop using nicotine.
-
Ear acupressure plus nicotine replacement to ease withdrawal in psychiatric inpatients
This study will test whether adding ear acupressure (ear seeds) to standard nicotine replacement therapy helps psychiatric inpatients who must stop smoking reduce withdrawal symptoms, cravings, and anxiety.
-
Sex differences in how menthol e-cigarettes appeal to people who smoke
This study tests whether men and women differ in how menthol e-cigarettes with or without nicotine appeal to smokers who have used e-cigarettes before.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.